{"url_path":"/sec/npce/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1528287/0001528287-26-000022-index.html","accession_number":"0001528287-26-000022","cik":"0001528287","ticker":"NPCE","issuer_name":"NeuroPace Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1528287/0001528287-26-000022-index.html","primary_entity_key":"0001528287","primary_entity_name":"NeuroPace Inc"},"word_count":79,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nRule 10b5-1 Trading Plans\n\nDuring the quarter ended March 31, 2026, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated any contracts, instructions, or written plans for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K.\n\n90"}